Results 1 to 10 of about 27,201 (202)

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

PLoS ONE, 2011
BackgroundOverexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently approved for the treatment of advanced ERBB2-positive breast cancer.
Rama Krishna Kancha, Nikolas von Bubnoff, Natalie Bartosch, Christian Peschel, Richard A Engh, Justus Duyster   +5 more
doaj   +3 more sources

Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. [PDF]

PLoS ONE, 2011
Lapatinib is an oral, small-molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptors (EGFR, or ErbB/Her) in solid tumors. Little is known about the effect of lapatinib on leukemia.
Huey-Lan Huang, Yu-Chieh Chen, Yu-Chuen Huang, Kai-Chien Yang, Hsin yi Pan, Shou-Ping Shih, Yu-Jen Chen   +6 more
doaj   +2 more sources

Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study [PDF]

PeerJ, 2023
Background Lapatinib is an oral small-molecule tyrosine kinase inhibitor indicated for advanced or metastatic HER2-positive breast cancer. In order to reduce the treatment cost, a high-fat enteral nutrition emulsion TPF-T was selected as a dose-sparing ...
Junfeng Zhu, Gaoqi Xu, Dihong Yang, Yu Song, Yinghui Tong, Sisi Kong, Haiying Ding, Luo Fang   +7 more
doaj   +4 more sources

Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells

Frontiers in Pharmacology, 2020
The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity. Lapatinib is further associated with mitochondrial toxicity and accumulation
Noëmi Johanna Roos, Noëmi Johanna Roos, Noëmi Johanna Roos, Diell Aliu, Diell Aliu, Jamal Bouitbir, Jamal Bouitbir, Jamal Bouitbir, Stephan Krähenbühl, Stephan Krähenbühl, Stephan Krähenbühl   +10 more
doaj   +2 more sources

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers

Heliyon, 2022
The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond to lapatinib therapy within 6 months. Therefore, potentiating the anti-tumor effect
Ziyin Tian, Yan Yang, He Wu, Yongye Chen, Hao Jia, Lei Zhu, Runjia He, Yibo Jin, Bei Zhou, Chunpo Ge, Yanxia Sun, Yun Yang   +11 more
doaj   +1 more source

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells

Frontiers in Pharmacology, 2021
Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients. However, its therapeutic efficacy is limited by primary or acquired resistance.
Min Ye, Min Ye, Wei Huang, Wei Huang, Rui Liu, Yingli Kong, Yang Liu, Yang Liu, Xiaole Chen, Xiaole Chen, Jianhua Xu, Jianhua Xu   +11 more
doaj   +1 more source

Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs

Scientific Reports, 2022
Epidermal growth factor receptors 1 and 2 (EGFR and HER2) are frequently overexpressed in various malignancies. Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2.
Shingo Maeda, Kosei Sakai, Kenjiro Kaji, Aki Iio, Maho Nakazawa, Tomoki Motegi, Tomohiro Yonezawa, Yasuyuki Momoi   +7 more
doaj   +1 more source

Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.

PLoS ONE, 2021
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gene ...
Jason J Zoeller, Michael F Press, Laura M Selfors, Judy Dering, Dennis J Slamon, Sara A Hurvitz, Joan S Brugge   +6 more
doaj   +1 more source

Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo

Biological Procedures Online, 2023
Background Resistance to HER2-targeted therapies, including the monoclonal antibody trastuzumab and tyrosine kinase inhibitor lapatinib, frequently occurs and currently represents a significant clinical challenge in the management of HER2-positive breast
Hao Liu, Sanbao Ruan, Margaret E. Larsen, Congcong Tan, Bolin Liu, Hui Lyu   +5 more
doaj   +1 more source

Synergistic Antitumor Activity and Mechanism of Lapatinib and Paclitaxel in Esophageal Cancer Cells

Zhongliu Fangzhi Yanjiu, 2021
Objective To investigate the anti-tumor activity and mechanism of lapatinib, paclitaxel and their combination on esophageal cancer cells EC109. Methods MTT assay was used to detect the effects of lapatinib (1, 2, 4, 8 μmol/L), paclitaxel (5, 10, 20, 40 ...
CHEN Tao, LI Xiongwei, SUN Xiaodong
doaj   +1 more source